Clinical Trials Logo

Ketosis clinical trials

View clinical trials related to Ketosis.

Filter by:

NCT ID: NCT03764631 Completed - Clinical trials for Diabetes Mellitus, Type 2

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

Start date: September 26, 2018
Phase:
Study type: Observational

The objectives of this study are to assess the risk of ketoacidosis, severe urinary tract infections, volume depletion, and dehydration associated in patients with T2DM initiating Empagliflozin compared to patient initiating a dipeptidyl peptidase-4 (DPP-4) inhibitors over a 12-month period of follow-up, including the month of Ramadan

NCT ID: NCT03727386 Completed - Clinical trials for Cognitive Impairments, Mild

The Effect of Vegetable Oil on Cognitive Functions of MCI Patients

DICe
Start date: November 19, 2019
Phase: N/A
Study type: Interventional

This study explores the feasibility of applying an intervention using vegetable oils (coconut and sunflower oils) on individuals diagnosed with Mild Cognitive Impairment. Participants will be divided into two groups and will either receive 30 ml of coconut or sunflower oil to be consumed daily for six months.

NCT ID: NCT03717896 Recruiting - Clinical trials for Diabetic Ketoacidosis

Thiamine as Adjunctive Therapy for Diabetic Ketoacidosis

Start date: November 21, 2018
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled trial to determine if administration of intravenous thiamine will lead to quicker resolution of acidosis in patients admitted to the hospital with diabetic ketoacidosis. The investigators will secondarily investigate whether thiamine improves cellular oxygen consumption, shortens intensive care unit (ICU) and hospital stay or decreases hospital resource utilization.

NCT ID: NCT03660189 Completed - Clinical trials for Diabetic Ketoacidosis

Two Bag System for Diabetic Ketoacidosis

2BagDKA
Start date: September 17, 2018
Phase: N/A
Study type: Interventional

This is a study investigating the best way to treat diabetic ketoacidosis (DKA) with intravenous (IV) fluids in the hospital. The purpose of this study is to determine whether the "two bag" system of administering IV fluids for the treatment of adults with DKA leads to a shorter time requiring intravenous insulin (a shorter time to anion gap closure), when compared to usual care the traditional "one bag" system of IV fluids. Participants will be assigned randomly to either the usual care group or the "two bag" system group. Based on studies performed in the past, the investigators predict that patients treated with the two bag system of IV fluids for DKA will have a significantly shorter time requiring treatment with intravenous insulin when compared to the traditional one bag system.

NCT ID: NCT03659825 Not yet recruiting - Hypoxia Clinical Trials

Ketone Esters for Optimization of Cognitive Performance in Hypoxia

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

This study will investigate the effects of ketone ester drinks on cognitive performance in hypoxia.

NCT ID: NCT03566524 Completed - Clinical trials for Ketosis Prone Diabetes

Study of Arginine and Nitric Oxide in Patients With Diabetes

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

This study will test the effect of citrulline versus placebo supplementation in ketosis-prone diabetes (KPD) patients on arginine and nitric oxide production and on glucose- and arginine-stimulated insulin secretion and arterial flow-mediated dilation.

NCT ID: NCT03564002 Recruiting - Obesity Clinical Trials

Metabolic Effects of Very Low Carbohydrate Ketogenic Diet in Subjects With Severe Obesity

Start date: October 1, 2016
Phase:
Study type: Observational

The very low carbohydrates diet (VLCKD) induces liver steatosis amelioration. Lysosomal acid lipase (LAL) deficiency plays a role in fats accumulation in liver. To date, no studies have assessed LAL activity in morbid obesity. The aim of our study is to evaluate VLCKD impact on metabolic/vascular parameters and LAL activity in obese patients. A VLCKD is administered for 25 days to 52 morbid obese patients (BMI 44.7±8.3 kg/m², age 49±12.5 years); at baseline and after diet we evaluated: BMI, glyco-lipidic pattern, abdominal ultrasonography (liver steatosis and visceral fat area) and flow-mediated dilation (FMD). In a subgroup of 20 patients we also tested lysosomal acid lipase (LAL)-activity. A group of healthy normal weight subjects (age 43±13, BMI 22.8±2.6 kg/m²) was also included in the study.

NCT ID: NCT03299543 Completed - Ketosis Clinical Trials

Comparison Between Breath Acetone and Blood Beta-Hydroxybutyrate

Start date: September 12, 2017
Phase:
Study type: Observational

Subjects will provide blood and breath samples to evaluate the relationship between breath acetone and two blood-bound species: beta-hydroxybutyrate and glucose. Subjects will be asked to provide breath and blood samples at a baseline visit and second optional visit. The two visits will be spaced approximately 3 hours apart.

NCT ID: NCT03182569 Completed - Clinical trials for Diabetic Ketoacidosis

Flexible Catheter for Insulin in Diabetes

Start date: December 11, 2016
Phase: N/A
Study type: Interventional

Use of a flexible subcutaneous catheter improves comfort in patients with DKA compared to the usual treatment with a metal needle.

NCT ID: NCT03128229 Completed - Clinical trials for Type 1 Diabetes Mellitus

Diabetic Kidney Alarm (DKA) Study

DKA
Start date: June 1, 2017
Phase:
Study type: Observational

The overarching goals of this study are to determine whether tubular dysfunction (elevated urine sodium, bicarbonate and amino acids) and injury (elevated kidney injury molecule 1 [KIM-1], neutrophil gelatinase-associated lipocalin [NGAL] and matrix metallopeptidase 9 [MMP9]) exist in diabetic ketoacidosis (age 3-18), whether it is reversible and whether it is related to uricosuria and copeptin. The investigators propose to study a cohort of youth (ages 3-18, n=40) with T1D who have serum and urine collection at DKA diagnosis and 3-month follow-up.